NASDAQ:RARE

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Retrieved on: 
Monday, January 8, 2024
U.S. FDA, FDA, EMA, Ageing, Osteogenesis imperfecta, Growth, Patient, OI

LONDON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its pipeline programs as well as an update on recent corporate developments.

Key Points: 
  • “2023 was a year of tremendous progress for Mereo.
  • “In addition, we significantly advanced the development of alvelestat, gaining valuable clarity on the regulatory path with both the FDA and EMA.
  • These developments are expected to further support our ongoing partnering activities for alvelestat.
  • We look forward to providing further updates on both setrusumab and alvelestat during the remainder of the year.